公司新闻 - 亚科因（Abbkine）—服务于细胞和蛋白研究全球用户

公司新闻 - 亚科因（Abbkine）—服务于细胞和蛋白研究全球用户

首页
技术中心
产品文献

或

货号	产品名称	文献标题	IF	杂志名称
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	Bulk and Single-Cell Transcriptomics Reveal That SCO2 Drives Psoriasis via Activating CCR7+ Dendritic Cell	5.600	International Journal of Molecular Sciences
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	SNW1 Promotes Lymphatic Metastasis in Bladder Cancer by Modulating SRPK1 Splicing	4.500	iScience
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	CPP-PNA Conjugate-Mediated Inhibition of pdxA Gene Impairs Vitamin B6 Biosynthesis and Growth in Acinetobacter baumannii	5.600	International Journal of Molecular Sciences
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	Shikonin ameliorates renal fibrosis by targeting HSPA1A to regulate lipid metabolism and inhibit ferroptosis	11.300	Phytomedicine
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	TRIM65 accelerates VSMC-derived foam cell formation and arteriosclerosis progression by inhibiting mitophagy	4.700	Molecular and Cellular Biochemistry
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	Glycogen Hydrogel Loaded with Schistosoma japonicas Peptide SJMHE1 Improves Skin Wound Healing	5.600	Biomolecules
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	Trifluoperazine upregulates ACSS2-related autophagy and promotes cerebral cognitive function in rats after sleep deprivation	4.500	iScience
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	PHB2 forms a mitochondrial calcium channel that drives Parkinson's disease	/	/
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	Draxin Induces Cognitive Impairment in Mice via Wnt/β-Catenin-Mediated Tau Phosphorylation	3.300	Journal of Integrative Neuroscience
BMU102	SuperKine™ 超敏型ECL发光液（飞克级）	TPPU protects against seizures and seizure-associated comorbidities by inhibiting the Akt/mTOR signaling pathway in KA-induced convulsant mice	7.000	Frontiers in Immunology

首页上一页 191 192 193 194 195 196 下一页尾页

赋能细胞研究与治疗 Enabling cell research and therapy

联系我们

全国服务热线： 400-6800-830

订购邮箱： service@abbkine.com

联系地址：武汉光谷生物医药加速器17号楼1号房2-3层

友情链接：

Copyright ©Abbkine Scientific Co., Ltd- 鄂ICP备10204150号-5

意见反馈

 在线咨询

扫码关注

微信公众号

返回顶部